MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease

References

• Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 2020;17:1–15.
   Web of Science ®Google Scholar
• Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
   PubMed Web of Science ®Google Scholar
• Economics DA. Economic analysis of motor neuron disease in Australia. Canberra: ACT; 2015.
   Google Scholar
• Dharmadasa T, Henderson RD, Talman PS, Macdonell RA, Mathers S, Schultz DW, et al. Motor Neurone disease: progress and challenges. Med J Aust. 2017;206:357–62.
   PubMed Web of Science ®Google Scholar
• Hogden A, Paynter C, Hutchinson K. How can we improve patient-centered care of motor neuron disease? Neurodegener Dis Manag 2020;10:95–101.
   PubMed Web of Science ®Google Scholar
• Aoun S, Birks C, Hogden A. S M. Public policy in MND care: the Australian perspective. In: Blank RH, Kurent JE, editors. Public Policy in ALS/MND Care. Singapore: Palgrave Macmillan; 2021.
   Google Scholar
• Aoun SM, Cafarella PA, Hogden A, Thomas G, Jiang L, Edis R. Why and how the work of Motor Neurone Disease Associations matters before and during bereavement: a consumer perspective. Palliat Care Soc Pract. 2021;15:26323524211009537.
   Google Scholar
• Bellgard MI, Snelling T, McGree JM. RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework. Orphanet J Rare Dis. 2019;14:176.
   PubMed Web of Science ®Google Scholar
• Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. 2016;6:e012054.
   PubMed Web of Science ®Google Scholar
• Talman P, Forbes A, Mathers S. Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database. Amyotroph Lateral Scler. 2009;10:79–84.
   PubMed Web of Science ®Google Scholar
• Vucic S, Higashihara M, Sobue G, Atsuta N, Doi Y, Kuwabara S, et al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology 2020;94:e1657–e1663.
   PubMed Web of Science ®Google Scholar
• Vucic S, Westeneng HJ, Al-Chalabi A, Van Den Berg LH, Talman P, Kiernan MC. Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:532–7. 7.
   PubMed Web of Science ®Google Scholar
• Hannaford A, Pavey N, van den Bos M, Geevasinga N, Menon P, Shefner JM, et al. Diagnostic utility of gold coast criteria in Amyotrophic lateral sclerosis. Ann Neurol. 2021;89:979–86.
   PubMed Web of Science ®Google Scholar
• Iacoangeli A, Lin T, Al Khleifat A, Jones AR, Opie-Martin S, Coleman JRI, et al. Genome-wide meta-analysis finds the ACSL5-ZDHHC6 locus is associated with ALS and links weight loss to the disease genetics. Cell Rep. 2020;33:108323.
   PubMed Web of Science ®Google Scholar
• Trabjerg BB, Garton FC, van Rheenen W, Fang F, Henderson RD, Mortensen PB, et al. ALS in Danish Registries: heritability and links to psychiatric and cardiovascular disorders. Neurol Genet. 2020;6:e398.
   PubMed Web of Science ®Google Scholar
• Kassubek J, Müller HP, Del Tredici K, Lulé D, Gorges M, Braak H, et al. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry. 2018;89:374–81.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89:156–61.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915–22.
   PubMed Web of Science ®Google Scholar
• Brooks B. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial. J Neurol Sci. 1994;124:96–107.
   PubMed Web of Science ®Google Scholar
• Brooks B, Miller R, Swash M, Munsat T. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497–503.
   PubMed Web of Science ®Google Scholar
• Chio A. ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol. 1999;246(Suppl 3):1–5.
   Google Scholar
• Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94–109.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics. 2008;5:516–27.
   PubMed Web of Science ®Google Scholar
• Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, Kollewe K, Paracka L, Dengler R, et al. Diagnostic criteria for amyotrophic lateral sclerosis: a multicentre study of inter-rater variation and sensitivity. Clin Neurophysiol. 2019;130:307–14.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975–8. 8.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:e451-60–e460.
   Google Scholar
• van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:496–501.
   PubMed Web of Science ®Google Scholar
• Chiò A, Canosa A, Gallo S, Cammarosano S, Moglia C, Fuda G, For the PARALS group, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 2011;77:1432–7.
   PubMed Web of Science ®Google Scholar
• Westeneng H-J, Debray TP, Visser AE, van Eijk RP, Rooney JP, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. The Lancet Neurology. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, Van Eijk RP, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2019 (in press):1–10.
   Google Scholar
• Park SB, Vucic S, Cheah BC, Lin CS, Kirby A, Mann KP, et al. Flecainide in amyotrophic lateral sclerosis as a neuroprotective strategy (FANS): a randomized placebo-controlled trial. EBioMedicine 2015;2:1916–22.
   PubMed Web of Science ®Google Scholar
• Oberstadt M, Stieler J, Simpong DL, Römuß U, Urban N, Schaefer M, et al. TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole. Sci Rep. 2018;8:2248.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Dalla Bella E, Chiò A, Mora G, Filippini G, Lauria G. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:1180–5.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416–22.
   PubMed Web of Science ®Google Scholar
• Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2015;126:803–9.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Simon NG, Geevasinga N, Menon P, Howells J, Park SB, et al. The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clin Neurophysiol. 2017;128:1075–82.
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Barkhaus PE, Burkhardt C, Castro J, Czell D, de Carvalho M, et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015;86:1172–9.
   PubMed Web of Science ®Google Scholar
• Menon P, Kiernan MC, Yiannikas C, Stroud J, Vucic S. Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol. 2013;124:410–6.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:17–28.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13:439–45.
   PubMed Web of Science ®Google Scholar
• Nicholson KA, Cudkowicz ME, Berry JD. Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all? Neurotherapeutics. 2015;12:376–83.
   PubMed Web of Science ®Google Scholar
• Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: review and new trial designs. Contemp Clin Trials Commun. 2018;12:1–8.
   PubMed Web of Science ®Google Scholar
• Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62–70.
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, van der Tweel I, Wokke JH, van den Berg LH. Sequential designs for clinical trials in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:202–7.
   PubMed Web of Science ®Google Scholar
• Bakker LA, Schröder CD, Tan HHG, Vugts S, van Eijk RPA, van Es MA, et al. Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. J Neurol Neurosurg Psychiatry. 2020;91:75–81.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, et al. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90:1331–1337.
   PubMedGoogle Scholar
• Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, et al. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology 2013;81:1350–5.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Qi K, Shelton K, Liss J, Berisha V, Shefner JM. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:61–7.
   PubMed Web of Science ®Google Scholar